How genes affect Ebola patients

Image
IANS New York
Last Updated : Oct 31 2014 | 11:40 AM IST

The Ebola virus affects different people differently, say researchers, adding that genetic factors could be behind this mild-to-deadly range of reactions to the virus.

While some people completely resist the disease, others suffer moderate to severe illness and recover, while those who are most susceptible succumb to bleeding, organ failure and shock.

These differences are not related to any specific changes in the Ebola virus itself; instead, the body's attempts to fight infection seems to determine disease severity.

"Our data suggest that genetic factors play a significant role in disease outcome," said Michael Katze from University of Washington.

For the study, the researchers examined the role of an individual's genetic makeup in the course of Ebola disease through a mouse model.

The researchers had obtained genetically diverse group of inbred laboratory mice to study locations on mouse genomes associated with influenza severity.

The scientists examined mice that they infected with a mouse form of the same species of Ebola virus causing the 2014 West Africa outbreak.

The scientists found that disease outcomes and variations in mortality rates were co-related to specific genetic lines of mice.

"The frequency of different manifestations of the disease across the lines of these mice screened so far are similar in variety and proportion to the spectrum of clinical disease observed in the 2014 West African outbreak," co-lead researcher Angela Rasmussen from University of Washington pointed out.

Survivors experienced more activity in genes that order blood vessel repair and the production of infection-fighting white blood cells.

The scientists noted that certain specialised types of cells in the liver could also have limited virus reproduction and put a dampener on systemic inflammation and blood clotting problems in resistant mice.

"We hope that medical researchers will be able to rapidly apply these findings to candidate therapeutics and vaccines," Katze stressed.

The study appeared in the journal Science.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 31 2014 | 11:38 AM IST

Next Story